Membrane Enzymology, Bijvoet Institute and Institute of Biomembranes, Utrecht University, The Netherlands.
Future Med Chem. 2009 Nov;1(8):1467-80. doi: 10.4155/fmc.09.112.
Platinum-based anticancer agents have been widely used in the clinic to successfully treat many different types of cancer. However, the therapeutic efficacy of platinum drugs is limited by serious side effects and the occurrence of inherent or acquired resistance of tumor cells. Nanoparticulate drug-delivery systems have the potential to reduce side effects and circumvent drug resistance. Among these, cisplatin nanocapsules represent a unique lipid formulation of cisplatin with an unsurpassed encapsulation efficiency, which dramatically increases the cytotoxicity of cisplatin in several cell lines in vitro. The mechanism responsible for the strongly enhanced cytotoxicity of the nanocapsules and the remarkable cell-line dependence will be reviewed. The requirements and possibilities for future successful therapeutic use of nanocapsules will be discussed, based on the mechanisms of cellular uptake of cisplatin nanocapsules and the first in vivo tests in a mouse model.
铂类抗癌药物在临床上被广泛用于成功治疗许多不同类型的癌症。然而,铂类药物的治疗效果受到严重副作用和肿瘤细胞固有或获得性耐药的限制。纳米药物递送系统有可能减少副作用并规避耐药性。在这些系统中,顺铂纳米囊代表了一种独特的顺铂脂质制剂,具有无与伦比的包封效率,显著提高了顺铂在体外几种细胞系中的细胞毒性。本文将综述纳米囊增强顺铂细胞毒性的机制及其显著的细胞系依赖性。基于顺铂纳米囊的细胞摄取机制和在小鼠模型中的首次体内试验,讨论了纳米囊未来成功治疗应用的要求和可能性。